Targeting nuclear factor-kappa B to overcome resistance to chemotherapy

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Chemoresistance is a significant obstacle in cancer treatment, stemming from complex mechanisms.
• These mechanisms include multi-drug resistance proteins, altered drug uptake, enhanced DNA repair, drug inactivation, and apoptosis evasion.
• The Nuclear Factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathway is frequently activated by chemotherapy drugs and plays a crucial role in cancer progression and resistance.

Purpose of the Study:

• To elucidate the role of NF-κB in cancer development and chemoresistance, with a specific focus on cisplatin resistance.
• To evaluate the potential benefits and drawbacks of targeting the NF-κB signaling pathway for therapeutic intervention.

Main Methods:

• Review of pre-clinical models demonstrating chemotherapy drug-induced NF-κB activation.
• Analysis of NF-κB's role in mediating resistance through various factors, including anti-apoptotic genes.
• Discussion of pharmacological strategies targeting NF-κB signaling.

Main Results:

• NF-κB activation is implicated in the development and progression of various cancers.
• The pathway contributes significantly to chemoresistance, particularly against agents like cisplatin.
• NF-κB controls numerous mediators, including genes that prevent programmed cell death (apoptosis).

Conclusions:

• NF-κB is a critical factor in cancer development and chemoresistance.
• Targeting NF-κB signaling presents a promising therapeutic strategy to overcome drug resistance in cancer.
• Pharmacological intervention in NF-κB pathways requires careful consideration of benefits and disadvantages.